Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04328012 · ClinicalTrials.gov registry record · Phase 2
COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With COVID-19
A Phase 2 study, sponsored by Bassett Healthcare.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT04328012: Clinical Trial Phase 2 study, sponsored by Bassett Healthcare.
NCT04328012 is a Phase 2 study that was terminated before completion, run by Bassett Healthcare. The registered enrollment target is 15 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04328012, a Phase 2 study, was terminated before completion, sponsored by Bassett Healthcare.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
In a randomized, double-blind, placebo-controlled, multi-center, Phase 2-like, investigator-directed trial, hospitalized adult patients with laboratory confirmed SARS-CoV-2 infection meeting inclusion and exclusion criteria, will be provided information on the trial, offered enrollment, and if informed consent provided, enrolled randomly in a 2:1 ratio to one of two groups: Group 1 standard care and losartan or Group 2 standard care and placebo. Patients will be followed for up to 60 days, with data collected to quantify the NCOSS over time (the primary objective), and for the trial's secondary objectives (see outcome measurements below).
Primary Outcome
difference in NCOSS scores between the different treatment groups
Interventions
- DRUG Placebo
- DRUG Losartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2020-04-06 |
| Est. Completion | 2021-12-01 |
| Phase | Phase 2 |
Why NCT04328012 stopped before completion
NCT04328012 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04328012 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04328012 about?
NCT04328012 is a clinical study titled "COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With COVID-19". In a randomized, double-blind, placebo-controlled, multi-center, Phase 2-like, investigator-directed trial, hospitalized adult patients with laboratory confirmed SARS-CoV-2 infection meeting inclusion and exclusion criteria, will be provided information on the trial, offered enrollment, and if infor...
What is the current status of trial NCT04328012?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2020-04-06. Estimated completion is 2021-12-01.
What interventions are being tested in trial NCT04328012?
The interventions under investigation include: Placebo (DRUG), Losartan (DRUG).
Who is sponsoring clinical trial NCT04328012?
This trial is sponsored by Bassett Healthcare, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04328012's enrollment target sits among peer trials
15 1919th of 2000 higher than 60 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI